Blair C. Mcnamara

Oncology

100 Church St S
New Haven, CT 06519

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Patient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility.

Patient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility.

Journal: Cureus

Published: February 27, 2026

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 14, 2026

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 14, 2026

Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status.

Real World Outcomes of Pembrolizumab and Reduced-Dose Lenvatinib in Recurrent Endometrial Cancer by Platinum and p53 Status.

Journal: Gynecologic oncology reports

Published: November 06, 2025

Experiences of OBGYN Administrative Chief Residents.

Experiences of OBGYN Administrative Chief Residents.

Journal: Journal of surgical education

Published: October 28, 2025

Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study.

Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 22, 2025

Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case.

Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case.

Journal: Gynecologic oncology reports

Published: July 28, 2025

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Journal: International journal of molecular sciences

Published: July 19, 2025

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.

Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.

Journal: Gynecologic oncology

Published: July 02, 2025

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.

Journal: Gynecologic oncology

Published: May 10, 2025

Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Journal: Cancer research communications

Published: May 08, 2025

Fertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor.

Fertility preserving, uterine sparing approach to a uterine extragonadal yolk sac tumor.

Journal: Gynecologic oncology reports

Published: April 15, 2025

Showing 1-12 of 52

Last Updated: 09/26/2026